Therapy (HBV)

Lamivudine Effective Only During Use

Published in Hepatitis Weekly, January 29th, 1996

Lamivudine effectively suppressed hepatitis B virus infection in chronic carriers treated at a Canadian research center, but the virus re-appeared in most patients when therapy was discontinued.

Researcher D. Lorne Tyrrell and colleagues from the University of Alberta's Glaxo Heritage Research Institute presented the findings at the First International Conference on Therapies for Viral Hepatitis, held December 11-15, 1995 in Kauai, Hawaii.

While new therapies for chronic hepatitis B virus carriers are urgently needed, the development of viral culture systems for hepadnaviruses had provided a method to rapidly screen for new antiviral agents.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry